Verano Holdings (VRNO) Non-Current Debt (2021 - 2026)
Verano Holdings' (VRNO) quarterly Non-Current Debt came in at $394.9 million in Q1 2026, down 2.2% year-on-year from $403.8 million in Q1 2025, and up 0.78% on a QoQ basis from $391.9 million in Q4 2025.
Verano Holdings (VRNO) Non-Current Debt (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Non-Current Debt data on file, last reported at $394.9 million in Q1 2026.
- On a quarterly basis, Non-Current Debt fell 2.2% year-over-year to $394.9 million in Q1 2026; TTM through Mar 2026 was $394.9 million, a 2.2% decrease from a year earlier, with the FY2025 full-year figure at $391.9 million, down 5.31% from the prior year.
- Non-Current Debt for Q1 2026 stood at $394.9 million, up from $391.9 million in the prior quarter.
- Over the last five years, Non-Current Debt for VRNO reached as high as $420.4 million in Q2 2023 and fell as low as $143.7 million in Q2 2022.
- Historically, Non-Current Debt has averaged $386.4 million across 5 years, with a median of $396.8 million in 2024.
- Across the five-year window, Non-Current Debt soared 192.44% in 2023 and retreated 5.85% in 2024, its largest moves.
- Year by year, Non-Current Debt stood at $388.5 million in 2022, then gained by 1.31% to $393.6 million in 2023, then grew by 5.13% to $413.8 million in 2024, then dropped by 5.31% to $391.9 million in 2025, then grew by 0.78% to $394.9 million in 2026.
- Per Business Quant data, the three most recent Non-Current Debt figures were $394.9 million in Q1 2026, $391.9 million in Q4 2025, and $397.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 394.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 394.95 Mn |
| Dec 31, 2025 | 391.88 Mn |
| Sep 30, 2025 | 397.82 Mn |
| Jun 30, 2025 | 403.27 Mn |
| Mar 31, 2025 | 403.83 Mn |
| Dec 31, 2024 | 413.85 Mn |
| Sep 30, 2024 | 420.15 Mn |
| Jun 30, 2024 | 395.78 Mn |
| Mar 31, 2024 | 391.27 Mn |
| Dec 31, 2023 | 393.64 Mn |
| Sep 30, 2023 | 415.48 Mn |
| Jun 30, 2023 | 420.38 Mn |
| Mar 31, 2023 | 415.34 Mn |
| Dec 31, 2022 | 388.54 Mn |
| Sep 30, 2022 | 392.14 Mn |
| Jun 30, 2022 | 143.75 Mn |
| Dec 31, 2021 | 289.93 Mn |